
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

August 8, 2018

PROQR THERAPEUTICS N.V.

**Zernikedreef 9
2333 CK Leiden**

The Netherlands

Tel: +31 88 166 7000

(Address, including ZIP Code, and Telephone Number,
including Area Code, of Registrant's Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Furnished as Exhibit 99.1 to this Report on Form 6-K are the unaudited financial statements of ProQR Therapeutics N.V. (the “Company”) for the three and six month periods ended June 30, 2018 and furnished as Exhibit 99.2 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. dated August 8, 2018, announcing the Company’s results for the three and six month periods ended June 30, 2018. The Company hereby incorporates by reference the information contained herein into the Company’s registration statement on Form F-3 (File No. 333-207245).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PROQR THERAPEUTICS N.V.

Date: August 8, 2018

By: /s/ Smital Shah

Smital Shah
Chief Financial Officer

INDEX TO EXHIBITS

Number	Description
99.1	Unaudited financial statements of ProQR Therapeutics N.V. for the three and six month periods ended June 30, 2018.
99.2	Press Release of ProQR Therapeutics N.V. dated August 8, 2018, announcing the Company's results for the three and six month periods ended June 30, 2018.

PROQR THERAPEUTICS N.V.
Index to Unaudited Condensed Consolidated Financial Statements

	PAGE
Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2018 and December 31, 2017	1
Unaudited Condensed Consolidated Statement of Comprehensive Loss for the Three Month and Six Month Periods ended June 30, 2018 and 2017	2
Unaudited Condensed Consolidated Statement of Changes in Equity for the Six Month Periods ended June 30, 2018 and 2017	3
Unaudited Condensed Consolidated Statement of Cash Flows for the Three Month and Six Month Periods ended June 30, 2018 and 2017	4
Notes to Unaudited Condensed Consolidated Financial Statements	5

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Financial Position

	June 30, 2018	December 31, 2017
	€ 1,000	€ 1,000
Assets		
Current assets		
Cash and cash equivalents	32,968	48,099
Prepayments and other receivables	1,312	2,064
Social securities and other taxes	1,014	396
Total current assets	35,294	50,559
Property, plant and equipment	2,208	2,505
Intangible assets	39	39
Total assets	37,541	53,103
Equity and liabilities		
Equity		
Equity attributable to owners of the Company	22,871	39,363
Non-controlling interests	(140)	(38)
Total equity	22,731	39,325
Current liabilities		
Borrowings	2,000	1,960
Trade payables	219	546
Social securities and other taxes	—	1,019
Pension premiums	—	—
Deferred income	2,358	347
Other current liabilities	4,209	4,622
Total current liabilities	8,786	8,494
Borrowings	6,024	5,284
Total liabilities	14,810	13,778
Total equity and liabilities	37,541	53,103

The notes are an integral part of these condensed consolidated financial statements.

PROQR THERAPEUTICS N.V.**Unaudited Condensed Consolidated Statement of Profit or Loss and OCI**

(€ in thousands, except share and per share data)

	Three month period ended June 30,		Six month period ended June 30,	
	2018	2017	2018	2017
	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Other income	971	265	1,470	658
Research and development costs	(5,990)	(7,552)	(13,675)	(15,582)
General and administrative costs	(2,649)	(2,892)	(5,321)	(5,196)
Total operating costs	(8,639)	(10,444)	(18,996)	(20,778)
Operating result	(7,668)	(10,179)	(17,526)	(20,120)
Finance income and expense	269	(1,184)	(590)	(1,721)
Result before corporate income taxes	(7,399)	(11,363)	(18,116)	(21,841)
Income taxes	(1)	—	(1)	(2)
Result for the period	(7,400)	(11,363)	(18,117)	(21,843)
Other comprehensive income	15	63	(11)	65
Total comprehensive income (attributable to owners of the Company)	(7,385)	(11,300)	(18,128)	(21,778)
Result attributable to				
Owners of the Company	(7,342)	(11,363)	(18,015)	(21,843)
Non-controlling interests	(58)	—	(102)	—
	(7,400)	(11,363)	(18,117)	(21,843)
Share information				
Weighted average number of shares outstanding ¹	31,926,746	23,991,685	31,924,319	23,733,885
Earnings per share attributable to the equity holders of the Company (expressed in Euro per share)				
Basic loss per share ¹	(0.23)	(0.47)	(0.57)	(0.92)
Diluted loss per share ¹	(0.23)	(0.47)	(0.57)	(0.92)

The notes are an integral part of these condensed consolidated financial statements.

- For this period presented in these financial statements, the potential exercise of share options is not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in this period.

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Changes in Equity

	Attributable to owners of the Company								
	Number of shares	Share Capital	Share Premium	Equity Settled Employee Benefit Reserve	Translation Reserve	Accumulated Deficit	Total	Non-controlling interests	Total Equity
		€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Balance at January 1, 2017	23,346,856	934	123,597	4,353	(15)	(75,733)	53,136	—	53,136
Result for the period	—	—	—	—	—	(21,843)	(21,843)	—	(21,843)
Other comprehensive income	—	—	—	—	65	—	65	—	65
Recognition of share-based payments	—	—	—	2,200	—	—	2,200	—	2,200
Issue of ordinary shares	758,012	30	3,193	—	—	—	3,223	—	3,223
Share options exercised	381	0	1	—	—	—	1	—	1
Balance at June 30, 2017	24,105,249	964	126,791	6,553	50	(97,576)	36,782	—	36,782
Balance at January 1, 2018	36,425,014	1,457	148,763	8,377	136	(119,370)	39,363	(38)	39,325
Result for the period	—	—	—	—	—	(18,015)	(18,015)	(102)	(18,117)
Other comprehensive income	—	—	—	—	(11)	—	(11)	—	(11)
Recognition of share-based payments	—	—	—	1,511	—	—	1,511	—	1,511
Share options exercised	—	—	23	—	—	—	23	—	23
Balance at June 30, 2018	36,425,014	1,457	148,786	9,888	125	(137,385)	22,871	(140)	22,731

The notes are an integral part of these condensed consolidated financial statements

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Cash Flows

	Three month period ended June 30,		Six month period ended June 30,	
	2018 € 1,000	2017 € 1,000	2018 € 1,000	2017 € 1,000
Cash flows from operating activities				
Net result	(7,400)	(11,363)	(18,117)	(21,843)
Adjustments for:				
— Depreciation	243	272	483	540
— Share-based compensation	640	1,273	1,511	2,200
— Financial income and expenses	(269)	1,184	590	1,721
— Net foreign exchange gain / (loss)	15	63	(11)	65
Changes in working capital	1,354	(1,275)	418	(1,368)
Cash used in operations	(5,417)	(9,846)	(15,126)	(18,685)
Corporate income tax paid	(1)	—	(1)	(2)
Interest received/(paid)	(6)	1	(7)	59
Net cash used in operating activities	(5,424)	(9,845)	(15,134)	(18,628)
Cash flow from investing activities				
Purchases of intangible assets	—	—	—	—
Purchases of property, plant and equipment	(182)	(48)	(186)	(93)
Net cash used in investing activities	(182)	(48)	(186)	(93)
Cash flow from financing activities				
Proceeds from issuance of shares, net of transaction costs	—	1,072	—	3,223
Proceeds from exercise of share options	23	—	23	1
Proceeds from borrowings	—	101	101	101
Proceeds from convertible loans	115	—	315	—
Net cash generated by financing activities	138	1,173	439	3,325
Net increase/(decrease) in cash and cash equivalents	(5,468)	(8,720)	(14,881)	(15,396)
Currency effect cash and cash equivalents	435	(1,070)	(250)	(1,483)
Cash and cash equivalents, at beginning of the period	38,001	52,111	48,099	59,200
Cash and cash equivalents at the end of the period	32,968	42,321	32,968	42,321

The notes are an integral part of these condensed consolidated financial statements.

PROQR THERAPEUTICS N.V.

Notes to Unaudited Condensed Consolidated Financial Statements

1. General information

ProQR Therapeutics N.V., or “ProQR” or the “Company”, is a development stage company domiciled in the Netherlands that primarily focuses on the development and commercialization of novel therapeutic medicines.

Since September 18, 2014, the Company’s ordinary shares are listed on the NASDAQ Global Market under ticker symbol PRQR.

The Company was incorporated in the Netherlands, on February 21, 2012 and was reorganized from a private company with limited liability to a public company with limited liability on September 23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.

ProQR Therapeutics N.V. is the ultimate parent company of the following entities:

- ProQR Therapeutics Holding B.V. (100%);
- ProQR Therapeutics I B.V. (100%);
- ProQR Therapeutics II B.V. (100%);
- ProQR Therapeutics III B.V. (100%);
- ProQR Therapeutics IV B.V. (100%);
- ProQR Therapeutics VI B.V. (100%);
- ProQR Therapeutics VII B.V. (100%);
- ProQR Therapeutics VIII B.V. (100%);
- ProQR Therapeutics IX B.V. (100%);
- ProQR Therapeutics I Inc. (100%);
- Amylon Therapeutics B.V. (majority interest).

ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (“ESOP Foundation”) and has full control over this entity.

As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to “ProQR” or the “Company” refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.

2. Significant Accounting Policies

These condensed consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”), in particular IAS 34 - Interim Financial Reporting. Certain information and disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2017. In the opinion of management, all adjustments, consisting of normal recurring nature, considered necessary for a fair presentation have been included in the condensed consolidated financial statements.

The Company's financial results have varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors.

The Company operates in one reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics.

3. Adoption of new and revised International Financial Reporting Standards

The accounting policies adopted in the preparation of the condensed consolidated financial statements are consistent with those applied in the preparation of the Company's annual financial statements for the year ended December 31, 2017. New Standards and Interpretations, which became effective as of January 1, 2018, did not have a material impact on our condensed consolidated financial statements.

4. Critical Accounting Estimates and Judgments

In the application of the Company's accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

(a) Share-based payments

Share options granted to employees and consultants are measured at the fair value of the equity instruments granted. Fair value is determined through the use of the Black-Scholes option-pricing model, which is considered the most appropriate model for this purpose by management.

Initially, the Company's ordinary shares were not publicly traded and consequently the Company needed to estimate the fair value of its share and the expected volatility of that value. Please refer to the Company's annual financial statements for the year ended December 31, 2017 for the assumptions used in those estimates. The value of the underlying shares was determined on the basis of the prior sale of company stock method. As such, the Company has benchmarked the value per share to external transactions of Company shares and external financing rounds.

For options granted from the moment of listing, the Company uses the closing price of the ordinary shares on the previous business day as exercise price of the options granted.

The result of the share option valuations and the related compensation expense is dependent on the model and input parameters used. Even though Management considers the fair values reasonable and defensible based on the methodologies applied and the information available, others might derive a different fair value for the Company's share options.

(b) Corporate income taxes

The Company recognizes deferred tax assets arising from unused tax losses or tax credits only to the extent that the Company has sufficient taxable temporary differences or there is convincing evidence that sufficient taxable profit will be

available against which the unused tax losses or unused tax credits can be utilized. Management's judgment is that such convincing evidence is currently not sufficiently available and a deferred tax asset is therefore only recognized to the extent that the Company has sufficient taxable temporary differences.

(c) Grant income

Grant income is not recognized until there is reasonable assurance that the Company will comply with the conditions attached to them. Grants are recognized in profit or loss on a systematic basis over the period the Company recognizes as expenses the related costs for which the grants are expected to compensate.

(d) Research and development expenditures

Research expenditures are currently not capitalized but are reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.

Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.

The condensed consolidated financial statements do not include all disclosures for critical accounting estimates and judgments that are required in the annual consolidated financial statements and should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2017.

5. Cash and Cash Equivalents

At June 30, 2018, the Company's cash and equivalents were € 32,968,000 as compared to € 48,099,000 at December 31, 2017. A significant portion of the cash balance is denominated in US dollars. The cash balances are held at banks with investment grade credit ratings. The cash at banks is at full disposal of the Company.

6. Current liabilities

At June 30, 2018 and December 31, 2017, the other current liabilities consisted principally of accruals for services provided by vendors not yet billed and other miscellaneous liabilities.

7. Borrowings

	June 30, 2018	December 31, 2017
	€ 1,000	€ 1,000
Innovation credit	5,000	4,899
Accrued interest on innovation credit	2,016	1,683
Convertible notes	1,008	662
Total borrowings	8,024	7,244
Current portion	(2,000)	(1,960)
	6,024	5,284

Innovation credit ("Innovatiekrediet")

On June 1, 2012, ProQR was awarded an Innovation credit by the Dutch government, through its agency RVO of the Ministry of Economic Affairs, for the Company's cystic fibrosis program. Amounts were drawn under this facility in the course of the years 2013 through 2018. The credit covers 35% of the costs incurred in respect of the program up to an initial maximum of € 5.0 million through March 31, 2018.

The credit is interest-bearing at a rate of 10% per annum. The credit, including accrued interest, is repayable in three instalments on November 30, 2018, November 30, 2019 and November 30, 2020, depending on the technical success of the program.

The assets which are co-financed with the granted innovation credit are subject to a right of pledge for the benefit of RVO.

Convertible loans

Convertible loans were issued to Amylon Therapeutics B.V. in 2017 and are interest-bearing at an average rate of 8% per annum. They are convertible into a variable number of ordinary shares within 36 months at the option of the holder or the Company in case financing criteria are met. Any unconverted loans become payable on demand after 24 months in equal quarterly terms.

8. Shareholders' equity

The authorized share capital of the Company amounting to € 7,200,000 consists of 90,000,000 ordinary shares and 90,000,000 preference shares with a par value of € 0.04 per share. At June 30, 2018, 36,425,014 ordinary shares were issued and fully paid in cash, of which 4,490,378 were held by the Company as treasury shares (31 December 2017: 4,503,149).

On October 2, 2015, the Company filed a shelf registration statement, which permitted: (a) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of \$ 200,000,000 of its ordinary shares, warrants and/or units; and (b) as part of the \$ 200,000,000, the offering, issuance and sale by us of up to a maximum aggregate offering price of \$ 60,000,000 of its ordinary shares that may be issued and sold under a sales agreement in one or more at-the-market offerings. In 2017, the Company has issued 976,477 shares pursuant to its current at-the-market offering program,

resulting in proceeds of € 4,138,000, net of € 127,000 of offering expenses. In 2018, no shares were issued pursuant to our ATM facility.

On June 28, 2017, the Company agreed to the issuance of 1,200,000 ordinary shares to institutional investors at an issue price of \$ 5.00 per share in a registered direct offering with gross proceeds of € 5,278,000. The closing of the offering was effected on July 3, 2017. Transaction costs amounted to € 414,000, resulting in net proceeds of € 4,864,000.

In November 2017, the Company consummated an underwritten public offering and concurrent registered direct offering of 6,397,498 ordinary shares at an issue price of \$ 3.25 per share. The gross proceeds from both offerings amounted to € 17,671,000 while the transaction costs amounted to € 988,000, resulting in net proceeds of € 16,683,000.

Translation reserve

The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

Share options

The Company operates an equity-settled share-based compensation plan which was introduced in 2013. Options may be granted to employees, members of the Supervisory Board, members of the Management Board and consultants. The quarterly compensation expenses included in operating costs for this plan in 2018 were € 1,511,000 (2017: € 1,273,000), of which € 873,000 (2017: € 627,000) was recorded in general and administrative costs and € 638,000 (2017: € 646,000) was recorded in research and development costs.

9. Other income

	Three month period ended June 30,	
	2018	2017
	€ 1,000	€ 1,000
Grant income	861	154
Rental income from property subleases	110	111
	971	265

On February 9, 2018, the Company entered into a partnership agreement with Foundation Fighting Blindness (FFB), under which FFB has agreed to provide funding of \$7.5 million for the pre-clinical and clinical development of QR-421a for Usher syndrome type 2A targeting mutations in exon 13.

On June 5, 2018, the Company entered into a partnership agreement with EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF) under which EBRP and EBMRF have agreed to provide funding of \$5.0 million for the clinical development of QR-313 for Dystrophic Epidermolysis Bullosa targeting mutations in exon 73.

In addition, funding was received in 2018 for our Huntington's disease program.

Grants are recognized in other income in the same period in which the related R&D costs are recognized.

10. Research and development costs

Research and development costs amount to € 5,990,000 for the quarter ended June 30, 2018 compared to € 7,552,000 for same period in 2017 and comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated costs.

11. General and administrative costs

General and administrative costs amount to € 2,649,000 for the quarter ended June 30, 2018 compared to € 2,892,000 for the quarter ended June 30, 2017.

12. Income taxes

Due to the operating losses incurred since inception the Company has no tax provisions as of the balance sheet date. Furthermore, no significant temporary differences exist between accounting and tax results. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company has not yet recognized any deferred tax asset related to operating losses.

13. Events after balance sheet date

No significant events have occurred after balance sheet date.

ProQR Therapeutics N.V.

Press Release August 8, 2018

**FINAL – FOR RELEASE**

ProQR Announces Financial Results for the Second Quarter of 2018

LEIDEN, the Netherlands, August 8, 2018 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced results for the second quarter of 2018.

“During the second quarter, we built up momentum across our pipeline of development programs, including the initiation of the WINGS study, the first clinical trial to evaluate QR-313 in patients with dystrophic epidermolysis bullosa. QR-313 is now our third program to enter clinical development,” said Daniel A. de Boer, chief executive officer of ProQR. “Over the next twelve months, we are looking forward to key clinical data read-outs from all three clinical development programs that could potentially provide broader validation of our platform in ophthalmology and dermatology. The clinical trial evaluating QR-110, our lead program in ophthalmology, in patients with Leber’s congenital amaurosis 10 remains on track for an interim data announcement later this year.”

Second Quarter 2018 Corporate Highlights

- Initiated WINGS, the first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene
 - Interim results expected in late 2018; full data expected in 2019
- Entered into a partnership with EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF)
 - ProQR will receive up to \$5 million in funding for the clinical development of QR-313
- Appointed Yi-Tao Yu, Ph.D., a professor of biochemistry and biophysics at the University of Rochester Medical Center, to the Company’s scientific advisory board
 - Dr. Yu’s research focuses on RNA editing and his expertise will help to develop the Company’s novel RNA editing technologies
- Presented at the European Cystic Fibrosis Society (ECFS) conference on eluforsen, formerly known as QR-010
 - Abstract title: *Exploratory immune assays distinguish healthy volunteer from CF patient cohorts and were validated in a dose escalation study of QR-010 in subjects with cystic fibrosis homozygous for the F508del CFTR mutation*
- With current cash on hand of €33.0 million (at June 30, 2018), ProQR’s operation is funded into late 2019

Subsequent Events

- A paper with preclinical data for QR-110 targeting Leber's congenital amaurosis 10 (LCA10) was published in, *Molecular Therapy – Nucleic Acids* an official journal of the American Society of Gene & Cell Therapy
 - The research was done in collaboration with scientists at the UCL Institute of Ophthalmology in London, United Kingdom and the Radboud University Medical Center in Nijmegen, the Netherlands
- Presented preclinical data for QR-421a for Usher syndrome at the International Symposium on Usher Syndrome (USH2018)
 - Abstract title: *Splice modulation to treat USH2A-associated retinal degeneration*

Financial Highlights

At June 30, 2018, ProQR held cash and cash equivalents of €33.0 million, compared to €48.1 million at December 31, 2017. Net cash used in operating activities during the three month period ended June 30, 2018 was €5.4 million, compared to €9.8 million for the same period last year.

Research and development costs totaled €6.0 million for the quarter ended June 30, 2018 compared to €7.6 million for the same period last year and comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated costs.

General and administrative costs decreased to €2.6 million for the quarter ended June 30, 2018 compared to €2.9 million for the quarter ended June 30, 2017.

Net loss for the three month period ended June 30, 2018 was €7.4 million or €0.23 per share, compared to a €11.3 million loss or €0.47 per share for the same period last year. For further financial information for the period ended June 30, 2018, please refer to the financial statements appearing at the end of this release.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber's congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Since 2012

About QR-110

QR-110 is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of Leber's congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. The p.Cys998X mutation is a substitution of one nucleotide in the pre-mRNA that leads to aberrant splicing of the mRNA and non-functional CEP290 protein. QR-110 is designed to restore wild-type CEP290 mRNA leading to the production of wild-type CEP290 protein by binding to the mutated location in the pre-mRNA causing normal splicing of the pre-mRNA. QR-110 is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and fast track status by the FDA.

About QR-313

QR-313 is a potential first-in-class RNA-based oligonucleotide designed to address the underlying cause of dystrophic epidermolysis bullosa (DEB) due to mutations in exon 73 of the COL7A1 gene. Mutations in this exon can cause loss of functional collagen type VII (C7) protein. Absence of C7 results in the loss of anchoring fibrils that normally link the dermal and epidermal layers of the skin together. QR-313 is designed to exclude exon 73 from the mRNA (exon skipping) and produce a functional C7 protein, thereby restoring functionality of the anchoring fibrils. The clinical development of QR-313 is supported with funding from EB Research Partnership and EB Medical Research Foundation. QR-313 has been granted orphan drug designation in the United States and the European Union.

About QR-421a

QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of vision loss in Usher syndrome 2A due to mutations in exon 13 of the USH2A gene. Mutations in this exon can cause loss of functional usherin protein that causes the disease. QR-421a is designed to exclude the genetic defect from the RNA in the eye, such that it leads to the expression of a shortened but functional protein, thereby modifying the underlying disease. QR-421a has received orphan drug designation in the United States and the European Union.

About eluforsen

Eluforsen, formerly known as QR-010, is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of the disease by targeting the mRNA in CF patients that have the F508del mutation. The technology was exclusively licensed from Massachusetts General Hospital. The F508del mutation results in the production of a misfolded CFTR protein that does not function normally. Eluforsen is a single agent designed to bind to the defective CFTR mRNA and to restore CFTR function. Eluforsen is designed to be self-administered via an optimized eFlow[®] Nebulizer (PARI Pharma GmbH). eFlow[®] is a small, handheld aerosol delivery device which nebulizes eluforsen into a mist inhaled directly into the lungs. Eluforsen has been granted orphan drug designation in the United States and the European Union and fast-track status by the FDA. The eluforsen project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 633545.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding QR-313 and the clinical development and the therapeutic potential thereof, statements regarding our pipeline of programs targeting DEB, statements regarding Eluforsen, formerly known as QR-010, and the clinical development and the therapeutic potential thereof, statements regarding QR-110 and the clinical development and therapeutic potential thereof, and statements regarding QR-421a and the clinical development and therapeutic potential thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.:

Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Financial Position

	June 30, 2018	December 31, 2017
	€ 1,000	€ 1,000
Assets		
Current assets		
Cash and cash equivalents	32,968	48,099
Prepayments and other receivables	1,312	2,064
Social securities and other taxes	1,014	396
Total current assets	35,294	50,559
Property, plant and equipment	2,208	2,505
Intangible assets	39	39
Total assets	37,541	53,103
Equity and liabilities		
Equity		
Equity attributable to owners of the Company	22,871	39,363
Non-controlling interests	(140)	(38)
Total equity	22,731	39,325
Current liabilities		
Borrowings	2,000	1,960
Trade payables	219	546
Social securities and other taxes	—	1,019
Pension premiums	—	—
Deferred income	2,358	347
Other current liabilities	4,209	4,622
Total current liabilities	8,786	8,494
Borrowings	6,024	5,284
Total liabilities	14,810	13,778
Total equity and liabilities	37,541	53,103

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Profit or Loss and OCI
(€ in thousands, except share and per share data)

	Three month period ended June 30,		Six month period ended June 30,	
	2018	2017	2018	2017
	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Other income	971	265	1,470	658
Research and development costs	(5,990)	(7,552)	(13,675)	(15,582)
General and administrative costs	(2,649)	(2,892)	(5,321)	(5,196)
Total operating costs	(8,639)	(10,444)	(18,996)	(20,778)
Operating result	(7,668)	(10,179)	(17,526)	(20,120)
Finance income and expense	269	(1,184)	(590)	(1,721)
Result before corporate income taxes	(7,399)	(11,363)	(18,116)	(21,841)
Income taxes	(1)	—	(1)	(2)
Result for the period	(7,400)	(11,363)	(18,117)	(21,843)
Other comprehensive income	15	63	(11)	65
Total comprehensive income (attributable to owners of the Company)	(7,385)	(11,300)	(18,128)	(21,778)
Result attributable to				
Owners of the Company	(7,342)	(11,363)	(18,015)	(21,843)
Non-controlling interests	(58)	—	(102)	—
	(7,400)	(11,363)	(18,117)	(21,843)
Share information				
Weighted average number of shares outstanding ¹	31,926,746	23,991,685	31,924,319	23,733,885
Earnings per share attributable to the equity holders of the Company (expressed in Euro per share)				
Basic loss per share ¹	(0.23)	(0.47)	(0.57)	(0.92)
Diluted loss per share ¹	(0.23)	(0.47)	(0.57)	(0.92)

1. For this period presented in these financial statements, the potential exercise of share options is not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in this period.

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Changes in Equity

	Attributable to owners of the company						Total	Non-controlling	Total equity
	Number of shares	Share capital	Share premium	Equity settled employee benefit reserve	Translation reserve	Accumulated deficit			
		€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Balance at January 1, 2017	23,346,856	934	123,597	4,353	15	75,733	53,136	—	53,136
Result for the period	—	—	—	—	—	21,843	21,843	—	21,843
Other comprehensive income	—	—	—	—	65	—	65	—	65
Recognition of share-based payments	—	—	—	2,200	—	—	2,200	—	2,200
Issue of ordinary shares	758,012	30	3,193	—	—	—	3,223	—	3,223
Share options exercised	381	0	1	—	—	—	1	—	1
Balance at June 30, 2017	24,105,249	964	126,791	6,553	50	97,576	36,782	—	36,782
Balance at January 1, 2018	36,425,014	1,457	148,763	8,377	136	119,370	39,363	38	39,325
Result for the period	—	—	—	—	—	18,015	18,015	102	18,117
Other comprehensive income	—	—	—	—	11	—	11	—	11
Recognition of share-based payments	—	—	—	1,511	—	—	1,511	—	1,511
Share options exercised	—	—	23	—	—	—	23	—	23
Balance at June 30, 2018	36,425,014	1,457	148,786	9,888	125	137,385	22,871	140	22,731

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Cash Flows

	Three month period ended June 30,		Six month period ended June 30,	
	2018	2017	2018	2017
	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Cash flows from operating activities				
Net result	(7,400)	(11,363)	(18,117)	(21,843)
Adjustments for:				
— Depreciation	243	272	483	540
— Share-based compensation	640	1,273	1,511	2,200
— Financial income and expenses	(269)	1,184	590	1,721
— Net foreign exchange gain / (loss)	15	63	(11)	65
Changes in working capital	1,354	(1,275)	418	(1,368)
<i>Cash used in operations</i>	<i>(5,417)</i>	<i>(9,846)</i>	<i>(15,126)</i>	<i>(18,685)</i>
Corporate income tax paid	(1)	—	(1)	(2)
Interest received/(paid)	(6)	1	(7)	59
Net cash used in operating activities	(5,424)	(9,845)	(15,134)	(18,628)
Cash flow from investing activities				
Purchases of intangible assets	—	—	—	—
Purchases of property, plant and equipment	(182)	(48)	(186)	(93)
Net cash used in investing activities	(182)	(48)	(186)	(93)
Cash flow from financing activities				
Proceeds from issuance of shares, net of transaction costs	—	1,072	—	3,223
Proceeds from exercise of share options	23	—	23	1
Proceeds from borrowings	—	101	101	101
Proceeds from convertible loans	115	—	315	—
Net cash generated by financing activities	138	1,173	439	3,325
Net increase/(decrease) in cash and cash equivalents	(5,468)	(8,720)	(14,881)	(15,396)
Currency effect cash and cash equivalents	435	(1,070)	(250)	(1,483)
Cash and cash equivalents, at beginning of the period	38,001	52,111	48,099	59,200
Cash and cash equivalents at the end of the period	32,968	42,321	32,968	42,321

